GlassScriptPhysician profile
Andrea Juarez
NPI 1508465139
$4,581.14
in general payments reported to CMS, 2019-2025
24 companies · $285 in 2025
The $285 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $722 · 2022: $1,444 · 2023: $1,330 · 2024: $800 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,391 · Education: $24.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,390.66 |
| Education | $24.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,491.08 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $738.83 | 2021-2024 | Xifaxan, Trulance |
| Redhill Biopharma INC. | $306.69 | 2021-2023 | Talicia |
| Daiichi Sankyo INC. | $279.46 | 2021-2024 | Injectafer |
| Madrigal Pharmaceuticals | $274.14 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $186.41 | 2023-2024 | Stelara, Tremfya, Simponi |
| Merck Sharp & Dohme LLC | $170.45 | 2021-2023 | Dificid |
| Intercept Pharmaceuticals, INC. | $141.33 | 2022-2023 | Ocaliva |
| Genzyme Corporation | $140.15 | 2022-2024 | |
| Ferring Pharmaceuticals INC. | $123.77 | 2021-2023 | Rebyota |
| Pfizer INC. | $122.15 | 2023-2024 | |
| Ardelyx, INC. | $107.85 | 2022-2023 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $86.41 | 2022-2023 | Entyvio, Gattex |
| Braintree Laboratories, INC. | $62.60 | 2021-2022 | |
| Evoke Pharma, INC. | $61.95 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $60.65 | 2022-2024 | |
| Qol Medical, LLC | $54.08 | 2022 | |
| Celgene Corporation | $33.52 | 2022-2023 | Zeposia |
| Lilly USA, LLC | $31.01 | 2024 | Omvoh |
| Nestle Healthcare Nutrition INC. | $25.31 | 2023 | |
| Celltrion USA INC. | $24.72 | 2024 | Zymfentra |
| Regeneron Healthcare Solutions, INC. | $23.29 | 2023 | Dupixent |
| Axonics, INC. | $18.21 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Juarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.